SCHEMBL1630757

SCHEMBL1630757

COc1ccc(S(=O)(=O)N(CC(=O)N2CCCC2c2ccc(F)cc2)c2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.46
ALDH1A1 P00352 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
GAA P10253 1/20 0.46
NPSR1 Q6W5P4 2/20 0.46
LMNA P02545 1/20 0.46
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46
OXTR P30559 3/20 0.46
AVPR1A P37288 3/20 0.46
PKM P14618 1/20 0.46
KEAP1 Q14145 3/20 0.45
NFE2L2 Q16236 3/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
CAMK2A Q9UQM7 1/20 0.43
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3423315 0.94 KEAP1 (0.51) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL1629490 0.94 KEAP1 (0.51) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL1630032 0.94 KEAP1 (0.51) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL1630528 0.92 OXTR (0.53) MAPTALDH1A1MEN1KMT2ANPSR1
SCHEMBL1630103 0.90 ALDH1A1 (0.52) MAPTALDH1A1KMT2ANPSR1LMNA
SCHEMBL1629094 0.90 CRHBP (0.52) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL1629400 0.90 OXTR (0.55) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL1632105 0.87 CRHBP (0.56) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL1919930 0.87 MDM4 (0.39) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL1630074 0.86 MAPT (0.49) MAPTALDH1A1MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932269-B2 Sulfonamides as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2011-04-26 US disclosed
US-7932269-B2 Sulfonamides as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2011-04-26 US disclosed
US-7932269-B2 Sulfonamides as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2011-04-26 US disclosed
WO-2009092642-A1 SULFONAMIDES AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-07-30 WO disclosed
US-20090186920-A1 SULFONAMIDES AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-07-23 US disclosed
US-20090186920-A1 SULFONAMIDES AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-07-23 US disclosed
US-20090186920-A1 SULFONAMIDES AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186920-A1 SULFONAMIDES AS OREXIN ANTAGONISTS HCRTR2, HCRTR1, NPSR1 MAPT 2667/4885ALDH1A1 2403/4885MEN1 1776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.